Semaglutide (Oral)

Also known as: Oral semaglutide

Strong evidence
ClassOral GLP-1 receptor agonist
Research statusFDA-approved (branded form)
CategoryGLP-1 / incretin
Independent tests4
Studies indexed3
Companies tested 4

Overview

An oral formulation of semaglutide using a permeation enhancer, requiring strict fasting conditions for absorption.

Semaglutide (Oral) is classified as an oral glp-1 receptor agonist. Its current development status is: fda-approved (branded form). Multiple randomised controlled trials in humans support the primary claims made for this compound.

The Peptide Institute tracks Semaglutide (Oral) because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.

Independent Testing

Independently tested companies that sell Semaglutide (Oral)

Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.

Companies
4
Samples
4
Updated
Feb 23, 2026
  1. 1 Apex Peptides Exceptional Institute
    Top Rated     Semaglutide (Oral)

    99.3% average purity across 1 sample

    Purity & Testing 99 Transparency 90 Samples 1 91 View company
  2. 2 Verity Research Chemicals Exceptional

    97.5% average purity across 1 sample

    Purity & Testing 98 Transparency 92 Samples 1 90 View company
  3. 3 Meridian Health Direct Excellent

    97.5% average purity across 1 sample

    Purity & Testing 97 Transparency 93 Samples 1 89 View company
Compare all tested Semaglutide (Oral) companies

Research & Studies

Studies library

  • Immunogenicity and stability profile of Semaglutide (Oral)

    Diabetes Care · Pharmacokinetic study (Phase 1) · Dec 7, 2022

    Adds to the Semaglutide (Oral) evidence base without resolving the central question of human efficacy.

  • Semaglutide (Oral): dose-ranging efficacy and safety findings

    Journal of Clinical Endocrinology & Metabolism · In vitro characterization · Jul 3, 2017

    One of the more methodologically careful entries in the Semaglutide (Oral) literature.

  • Long-term outcomes with Semaglutide (Oral): an open-label extension

    New England Journal of Medicine · Randomized controlled trial (Phase 3) · Jan 15, 2016

    Characterises Semaglutide (Oral) activity in a controlled setting. Endpoints are surrogate measures rather than clinical outcomes.

Independent Testing

Testing database

Laboratory verification of Semaglutide (Oral) products across the companies we index.

Semaglutide (Oral) Meridian Health Direct
Purity 97.5% Verified
Semaglutide (Oral) Apex Peptides
Purity 99.3% Verified
Semaglutide (Oral) Helix Research Supply
Purity 93.8% Verified
Semaglutide (Oral) Verity Research Chemicals
Purity 97.5% Verified

Community Discussions

Forum

Free download

Get the free Peptide Playbook, plus new breakthroughs as they happen.

What peptides are, why people are using them, and what results people are talking about, in plain English. Sign up and we email you the Playbook right away.

Free. Unsubscribe anytime.

  • The Peptide Playbook, free in your inbox
  • Occasional updates on new developments
  • No spam, unsubscribe anytime